glp 1 novo Nordisk launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry Novo's Wegovy becomes first GLP-1

Neurochem Res (2008) 33(9):184551

Over 72 weeks patients without diabetes lost 15%, 19%, and 21% of body weight on the 5, 10, and 15 mg weekly SQ injections, respectively

Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications

Furthermore, GLP-1 RAs have demonstrated significant reductions in major adverse cardiovascular events (MACE), heart failure hospitalizations, and all-cause mortality in patients with T2DM, and obesity, benefits not consistently observed with CPAP in randomized cardiovascular outcome trials [2527]